Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 16502413

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Cancer
Publication date
2006 Apr 1
First author
Thomas DA

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Thomas DA
      type
      Author
    2. name
      Faderl S
      type
      Author
    3. name
      O'Brien S
      type
      Author
    4. name
      Bueso-Ramos C
      type
      Author
    5. name
      Cortes J
      type
      Author
    6. name
      Garcia-Manero G
      type
      Author
    7. name
      Giles FJ
      type
      Author
    8. name
      Verstovsek S
      type
      Author
    9. name
      Wierda WG
      type
      Author
    10. name
      Pierce SA
      type
      Author
    11. name
      Shan J
      type
      Author
    12. name
      Brandt M
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Thomas DA
      type
      Author
    2. name
      Faderl S
      type
      Author
    3. name
      O'Brien S
      type
      Author
    4. name
      Bueso-Ramos C
      type
      Author
    5. name
      Cortes J
      type
      Author
    6. name
      Garcia-Manero G
      type
      Author
    7. name
      Giles FJ
      type
      Author
    8. name
      Verstovsek S
      type
      Author
    9. name
      Wierda WG
      type
      Author
    10. name
      Pierce SA
      type
      Author
    11. name
      Shan J
      type
      Author
    12. name
      Brandt M
      type
      Author
    bibliography ids
    1. nci-bib-b5d6f51be1dfb13bae544c2b
    book metadata
    content sha256
    b230c470ac95aa69732f140810700c7afb0fd3e28109404f120373fcca901efa
    document type
    citation
    dois
    1. 10.1002/cncr.21776
    electronic publication date
    display
    Source null
    precision
    missing
    year
    Source null
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:16502413
    immutable id
    pubmed:16502413@b230c470ac95aa69732f140810700c7afb0fd3e28109404f120373fcca901efa
    journal
    abbreviation
    Cancer
    issn electronic
    Source null
    issn print
    0008-543X
    issue
    7
    name
    Cancer
    nlm unique id
    0374236
    pages
    1569-80
    volume
    106
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      16502413
      provenance
      batch id
      a181c30258a88d182e78
      provider
      NCBI PubMed ESummary
      record sha256
      78a00d173d77ffdf75212102b02e368ce8e6de6e9add67d9d2ce81d1e2783a59
      response sha256
      558e0dce453ae424567844b062522ebd1d27363c3312c81dbf6f32a8ff08da24
      retrieved at
      2026-09-09T23:46:03.896343+00:00
      publication date
      display
      2006 Apr 1
      precision
      day
      year
      2006
      publication types
      1. Clinical Trial
      2. Journal Article
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/16502413/
      title
      Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.

      Preserved source evidence · Independent clinical review pending · Not medical advice